Kodama Junichi, Seki Noriko, Fukushima Chikako, Kusumoto Tomoyuki, Nakamura Keiichiro, Hongo Atsushi, Hiramatsu Yuji
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Oncol Lett. 2012 Nov;4(5):1122-1124. doi: 10.3892/ol.2012.891. Epub 2012 Aug 31.
The purpose of this study was to evaluate the changes in plasma soluble fibrin (SF) levels over time in gynecologic cancer patients following surgery. Furthermore, we examined the duration of the coagulation stage and determined a suitable duration for which thromboprophylaxis with anticoagulant agents should be administered. We retrospectively studied 311 patients with invasive gynecologic cancer who underwent surgery at Okayama University Hospital, Japan. The plasma SF levels were measured serially prior to the operation and on postoperative days 0, 1, 3, 5, 7, 10, 14, 21 and 28. The plasma SF levels increased rapidly, peaked on postoperative day 1 and then decreased. The SF levels of patients with venous thromboembolism (VTE) were significantly different from those of VTE-negative patients on postoperative days 0-10. The SF levels on each day did not significantly differ between patients treated with chemical anticoagulants and those treated mechanically. The plasma SF levels were elevated (≥7.0 μg/ml) in 159 of the 311 patients (51.1%) on one of the days when these levels were measured. Among the patients with elevated plasma SF levels, 110 patients (69.2%) peaked on days 0-3 and only 9 patients (5.7%) peaked on days 21-28. Although only 1 of the 14 patients (7.1%) who showed peak levels on day 14 had undergone chemotherapy following surgery, 8 of the 9 patients (88.9%) whose levels peaked on days 21-28 had undergone chemotherapy following surgery (P= 0.0002). In conclusion, the plasma SF levels increased rapidly, peaked on postoperative day 1 and then decreased. These levels peaked within 14 days of surgery in most cases. Therefore, chemical thromboprophylaxis may be administered for at least up to 14 days following surgery.
本研究的目的是评估妇科癌症患者术后血浆可溶性纤维蛋白(SF)水平随时间的变化。此外,我们检查了凝血阶段的持续时间,并确定了使用抗凝剂进行血栓预防的合适持续时间。我们回顾性研究了311例在日本冈山大学医院接受手术的浸润性妇科癌症患者。在手术前以及术后第0、1、3、5、7、10、14、21和28天连续测量血浆SF水平。血浆SF水平迅速升高,在术后第1天达到峰值,然后下降。术后0至10天,静脉血栓栓塞(VTE)患者的SF水平与VTE阴性患者的SF水平有显著差异。接受化学抗凝治疗的患者和接受机械治疗的患者每天的SF水平没有显著差异。在测量血浆SF水平的某一天,311例患者中有159例(51.1%)的血浆SF水平升高(≥7.0μg/ml)。在血浆SF水平升高的患者中,110例(69.2%)在第0至3天达到峰值,只有9例(5.7%)在第21至28天达到峰值。虽然在术后第14天达到峰值水平的14例患者中只有1例(7.1%)在术后接受了化疗,但在第21至28天达到峰值水平的9例患者中有8例(88.9%)在术后接受了化疗(P = 0.0002)。总之,血浆SF水平迅速升高,在术后第1天达到峰值,然后下降。这些水平在大多数情况下在术后14天内达到峰值。因此,术后化学血栓预防至少可进行14天。